Clinical applications of bivalirudin in the cardiac catheterization laboratory

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 2, 2011, Pages 140-149

  Thompson, Keith A ^a   Philip, Kiran J ^a   Schwarz, Ernst R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Bivalirudin; Percutaneous intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); CORONARY STENT; COST BENEFIT ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; HEALTH CARE COST; HEART CATHETERIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOADING DRUG DOSE; MEDICAL SOCIETY; MULTICENTER STUDY (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ANTITHROMBINS; DRUG COSTS; HEART CATHETERIZATION; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS;

EID: 79960330594     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410385682     Document Type: Review

References (42)

1. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996;93(4):667-671. (Pubitemid 26052451)
2. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995;333(12):764-769.
3. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002; 106(3): V275-V284. (Pubitemid 35279149)
4. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a lowmolecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97(3):251-256. (Pubitemid 28067310)
5. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vase Surg. 2001;33(3):587-594. (Pubitemid 32215610)
6. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 suppl): 64S-94S.
7. Weitz JI, Hirsh J. New anticoagulant drags. Chest. 2001;119(1 suppl):95S-107S.
8. Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol. 2007;100(3):417-424. (Pubitemid 47094690)
9. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002; 143(5):847-853. (Pubitemid 34595343)
10. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93(9): 1092-1096. (Pubitemid 38521035)
11. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein Ilb/IIIa blockade compared with heparin and planned glycoprotein Ilb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853-863. (Pubitemid 37430344)
12. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21): 2203-2216. (Pubitemid 44791162)
13. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-2230. (Pubitemid 351724451)
14. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149- 1159.
15. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7):688-696.
16. Tavano D, Visconti G, D'Andrea D, et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009;104(9):1222-1228.
17. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein Ilb/IIIa blockade vs heparin and planned glycoprotein Ilb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292(6):696-703. (Pubitemid 39062523)
18. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111(16):2099- 2106. (Pubitemid 40577905)
19. Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2010;105(3):323-332.
20. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294(10): 1224-1232. (Pubitemid 41352110)
21. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103(7):961-966. (Pubitemid 32183801)
22. Brener SJ, Bhatt DL, Moliterno DJ, Schneider JP, Ellis SG, Topol EJ. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol. 2003; 92(12):1468-1471. (Pubitemid 37532576)
23. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110(8):994-998. (Pubitemid 39128625)
24. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47(1):216-235. (Pubitemid 43005194)
25. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142(6):952-959. (Pubitemid 33131801)
26. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):el-el57.
27. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein Ilb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol. 2000;35(5):1103-1115. (Pubitemid 30206882)
28. Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004;147(3):457-462. (Pubitemid 38880865)
29. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369(9565):907-919. (Pubitemid 46400858)
30. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(25):2205-2241.
31. Venkatesh K, Mann T. Transitioning from heparin to bivalirudin in patients undergoing ad hoc transradial interventional procedures: a pilot study. J Invasive Cardiol. 2006;18(3):120-124.
32. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591-602.
33. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA. 2007;298(21):2497-2506. (Pubitemid 350223536)
34. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176-2190.
35. Lincoff AM, Steinhubl SR, Manoukian SV, et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv. 2008;1(6):639-648.
36. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)
37. Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein Ilb/IIIa inhibition versus heparin with routine glycoprotein Ilb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008;52(22):1758-1768.
38. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol. 2004;44(9):1792-1800. (Pubitemid 39424077)
39. Caruba T, Chaib A, Danchin N, et al. [Clinical and economical evaluation of bivalirudin during percutaneous coronary interventions]. Ann Cardiol Angeiol (Paris). 2010;59(2):72-78.
40. De Luca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analyis of randomised trials. Thromb Haemost. 2009;102(3):428-436.
41. Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31(5):561-572.
42. Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303(21):2156-2164.